Hypera SA
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.5
- Today's High:
- $8.04
- Open Price:
- $7.98
- 52W Low:
- $6.8444
- 52W High:
- $10.0085
- Prev. Close:
- $8
- Volume:
- 1600
Company Statistics
- Market Cap.:
- $4.74 billion
- Book Value:
- 17.467
- Revenue TTM:
- $8.09 billion
- Operating Margin TTM:
- 32.03%
- Gross Profit TTM:
- $4.76 billion
- Profit Margin:
- 21.45%
- Return on Assets TTM:
- 7.24%
- Return on Equity TTM:
- 16.41%
Company Profile
Hypera SA had its IPO on under the ticker symbol HYPMY.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Hypera SA has a staff strength of 0 employees.
Stock update
Shares of Hypera SA opened at $7.98 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.5 - $8.04, and closed at $7.5.
This is a -6.25% slip from the previous day's closing price.
A total volume of 1,600 shares were traded at the close of the day’s session.
In the last one week, shares of Hypera SA have slipped by -3.23%.
Hypera SA's Key Ratios
Hypera SA has a market cap of $4.74 billion, indicating a price to book ratio of 2.5224 and a price to sales ratio of 0.7222.
In the last 12-months Hypera SA’s revenue was $8.09 billion with a gross profit of $4.76 billion and an EBITDA of $2.69 billion. The EBITDA ratio measures Hypera SA's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Hypera SA’s operating margin was 32.03% while its return on assets stood at 7.24% with a return of equity of 16.41%.
In Q2, Hypera SA’s quarterly earnings growth was a positive 10.5% while revenue growth was a positive 17.7%.
Hypera SA’s PE and PEG Ratio
- Forward PE
- 13.986
- Trailing PE
- 13.6364
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.55 per share while it has a forward price to earnings multiple of 13.986 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Hypera SA’s profitability.
Hypera SA stock is trading at a EV to sales ratio of 0.9055 and a EV to EBITDA ratio of 2.4739. Its price to sales ratio in the trailing 12-months stood at 0.7222.
Hypera SA stock pays annual dividends of $1.231 per share, indicating a yield of 2.97% and a payout ratio of 45.18%.
Balance sheet and cash flow metrics
- Total Assets
- $23.81 billion
- Total Liabilities
- $4.09 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $214.61 million
- Dividend Payout Ratio
- 45.18%
Hypera SA ended 2024 with $23.81 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $23.81 billion while shareholder equity stood at $11.05 billion.
Hypera SA ended 2024 with $0 in deferred long-term liabilities, $4.09 billion in other current liabilities, 4478126000.00 in common stock, $451.94 million in retained earnings and $7.37 billion in goodwill. Its cash balance stood at $2.14 billion and cash and short-term investments were $2.14 billion. The company’s total short-term debt was $1,770,451,000 while long-term debt stood at $8.09 billion.
Hypera SA’s total current assets stands at $8.00 billion while long-term investments were $0 and short-term investments were $-308074000.00. Its net receivables were $3.21 billion compared to accounts payable of $1.07 billion and inventory worth $2.30 billion.
In 2024, Hypera SA's operating cash flow was $0 while its capital expenditure stood at $214.61 million.
Comparatively, Hypera SA paid $0.45 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.5
- 52-Week High
- $10.0085
- 52-Week Low
- $6.8444
- Analyst Target Price
- $
Hypera SA stock is currently trading at $7.5 per share. It touched a 52-week high of $10.0085 and a 52-week low of $10.0085. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $8.76 and 200-day moving average was $8.2 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 3.7% are held by institutions.
Frequently Asked Questions About Hypera SA
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex ” A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.